Articles related to MULTIPLE SCLEROSIS (MS)

In the evolving landscape of MS treatment, the strategic choice between early aggressive and escalation therapies is critical. Understanding the nuances of patient-specific factors, such as age and disease activity, can significantly influence outcomes and guide effective management.

At ECTRIMS-ACTRIMS 2023, pivotal studies like the OLIKOS and MIRANTIBUS trials have highlighted the evolving dynamics in MS treatment, particularly emphasizing the shift towards more patient-centric and effective therapeutic approaches.

Multiple sclerosis (MS) is a complex disease with symptoms often mistaken for other conditions, making early detection crucial for effective treatment.

A recent study found that more than 39% of MS patients had vitamin D levels below 20 ng/mL, which is considered deficient. This deficiency was associated with poorer cognition and greater disability, underscoring the importance of monitoring and managing vitamin D levels in MS patients.

Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

This innovative AI model, presented at the 2023 AACC Annual Scientific Meeting, demonstrates the potential to identify MS risk years in advance, offering a new horizon in early detection and patient care. Explore the full findings to understand how this could impact your practice.